Motility Disorder of Intestine, Ondansetron, Small Bowel Water
Conditions
Keywords
ondansetron, small bowel water
Brief summary
This is a double-blind, two period, two treatment crossover trial of ondansetron verses placebo studying the effects of ondansetron in the small and large bowel, specifically its effects on the amount of water in the gut, measured by MRI.
Detailed description
If participants interested to take part the investigators will ask some questions to check participants are eligible to take part. Part of this involves measuring height, weight and having an electrocardiogram (ECG) to assess the heart. This is non-invasive and is achieved by attaching stickers across participants' chest. If participants are eligible the investigators will invite them to join the study, asked to sign a consent form and arrange for them to come to 4 study days. Study Days The study days take place at the 3T Acheiva MRI scanner at the Sir Peter Mansfield Imaging Centre. This is located on the University Park campus. The day before each scanning day participants will be asked to eat and drink as normal, avoiding beans or pulses and abstain from alcohol. The investigators ask that participants avoid strenuous exercise, and if they smoke to continue as normal. On the morning of the day 1 of the study participants should come to the MRI scanner around 8 o'clock in the morning. They should not have anything to eat or drink at all, unless they need a sip of water to swallow essential medicines. The investigators will confirm that it is still safe for participants to be scanned and participants will then change into surgical scrubs (provided) to begin the study. Participants will be randomly assigned to take either ondansetron, the anti-sickness tablet, for the first 2 visits or a dummy tablet (placebo) three times daily. They will be overcoated tablets so that neither participants nor the research team can tell which one it is. Participants will then have an MRI scan, during which the investigators will scan the body in different ways. A separate information sheet tells participants more about this. After these are done the investigators will give participants a meal supplement drink called Fortisip. Participants will have around 10 minutes to finish the drink. As soon as participants finish the MRI will be repeated. Participants will then have 3 further MRI scans, 2, 4 and 6 hours after the meal. After the last scan the investigators will give participants another dose of either the ondansetron or the placebo, and 20mls of a laxative called lactulose. The investigators will provide participants with tablets and the laxative for the following day at home. Day 2 of the study participants can have a normal day at home, however the investigators ask that participants refrain from strenuous exercise, avoid alcohol, beans and pulses and continue a usual smoking habit if applicable. Participants are asked to take the tablet (either ondansetron or placebo) three times a day (in the morning, midday and evening) and 20mls of the laxative in the morning and evening. They are also asked to take 5 MRI marker tablets at 8pm, and take a timestamped photo or video so the investigators can ensure these are taken at the correct time. The marker tablets will be used to measure the speed of food along the gut on the scan on day 3. On day 3 participants are asked to return for another day of scanning at the Sir Peter Mansfield Imagine Centre. Again, participants should come to the MRI scanner around 8 o'clock in the morning. They should not have anything to eat or drink at all, unless a sip of water is needed to swallow essential medicines. The investigators will re-confirm that it is still safe for participants to be scanned and participants will then change into surgical scrubs (provided) to begin the study. Participants will receive a further dose of the ondansetron or placebo tablet, then have an MRI scan before drinking the same Fortisip meal supplement and the lactulose. Once participants have finished the drink they will have 2 further MRI scans, 2 and 4 hours after the meal. Participants can then leave for the day. The investigators ask that participants come back to repeat the above 3 day procedure once more, taking the alternative tablet the second time around. Study periods will normally be one week apart. It is very important that participants attend both study periods as the investigators will compare the results from one week to the other.
Interventions
DRUGOndansetron 8mg
ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
DIAGNOSTIC_TESTabdominal MRI
serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
DRUGLactulose
Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
DRUGPlacebo oral capsule
overcoated placebo tablet, identical to the ondansetron
Sponsors
University of Nottingham
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Masking description
Double blind
Intervention model description
double-blind, two-period, two-treatment crossover trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* aged 18 or older * able to give informed consent
Exclusion criteria
* Pregnancy declared by candidate * History declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function, congenital long QT syndrome or QTc \>450msecs for males or 470 msecs for female on screening ECG. * A positive diagnosis of irritable bowel syndrome based on the Rome IV criteria questionnaire * Reported history of previous resection of the oesophagus, stomach or intestine (excluding appendix) * Intestinal stoma * Any medical condition making participation potentially compromising participation in the study e.g. diabetes mellitus, respiratory disease limiting ability to lie in the scanner, known allergy to one of the food products * Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury * Will not agree to dietary restrictions required during the MRI study day * Unable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study (Selective serotonin reuptake inhibitors and low dose tricyclic antidepressants will be recorded but will not be an
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| small bowel water content | 0-6 hours post meal | Change from baseline in area under the curve (AUC) small bowel water content |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| small bowel motility (global motility score, arbitrary units) | 2 and 4 hours postprandially | Change from baseline motility over the study using cine MRI. An increased value indicates increased small bowel motility |
| Weighted average position score (WAPS) | baseline on day 3 | MRI method of assessing colonic transit using MR marker pills ingested 12 hours before the scan. A lower value indicates faster whole gut transit |
| T1 of the ascending colon (T1AC) | baseline on day 3 | MRI measure of water content in the ascending colon.Change from baseline in AUC T1AC from 0-4 hours. A higher value indicates more watery ascending colon content. |
Countries
United Kingdom
Outcome results
None listed